• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

FDA Brings Awareness to Driving and OTC Drug Dangers

July 11, 2014 by admin

 

 

The Food and Drug Administration (FDA) made it known last week that motor vehicles and certain medications don’t mix. As reported by Kathryn Roethel in the San Francisco Gate, some of those medications are over-the-counter drugs “that are probably in your medicine cabinet.”

 

Antidiarrheals, motion sickness medications, and antihistamines are non-prescription meds the FDA called out last week in an online briefing about the dangers of driving while using common drugs. Dr. Ali Mohamadi, a medical officer at the FDA’s Center for Drug Evaluation and Research, explained that because these medications are available over the counter, many people discount their risks.

“The drugs’ side effects include drowsiness, slow reflexes and faulty perception of time and distance. Mohamadi recommends patients pay extra attention to instructions and warnings on these products’ Drug Facts labels,” writes Roethel. “Earlier this year the FDA took other steps to decrease medication-related drowsy driving. The agency required makers of two popular prescription sleep aids, Lunesta and Ambien, to cut their starting doses in half, decreasing the amount of drug still in patients’ blood during the next morning’s commute.”

 

Roethel points out that the National Highway Traffic Safety Administration estimates about 2.5% of fatal car accidents, and 2% of injury crashes involved drowsy drivers. That’s up to 6,000 fatal collisions each year. For the FDA’s online presentation about OTC medications and impaired driving, go to http://1.usa.gov/1qU74eu

Filed Under: Articles, Blog

Primary Sidebar

More to See

Snoring, American Sleep and Breathing Academy and the NY Times

August 23, 2022 By admin

Jazz Pharma Presents 17 New Posters for SLEEP 2022

June 6, 2022 By admin

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • SUPPORT AND PROMOTE DENTAL SLEEP MEDICINE IN 2023!
  • Snoring, American Sleep and Breathing Academy and the NY Times
  • Jazz Pharma Presents 17 New Posters for SLEEP 2022
  • AJMC Hypes SLEEP 2022
  • Avadel Pharmaceuticals’ Stock Falls

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2023 · Sleep Diagnosis and Therapy